chufangao/CTO huggingface dataset:
Clinical trial NCT03634228: Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
Official title: A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: This study was terminated early due to lack of adequate response, and did not move to the Phase II portion of the study
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-17
Primary completion date: 2022-04-03
Completion date: 2022-04-03
Clinical trial NCT03644589: Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
Official title: A Phase II Trial Evaluating Safety and Efficacy of Pembrolizumab and Cisplatin in Patients With Advanced Triple Negative Breast Cancer
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-01
Primary completion date: 2021-10-30
Completion date: 2022-10-30
Plan to share individual participant data: NO
Clinical trial NCT03894007: Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
Official title: Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Acronym: PREDIXIIHER2
Sponsor: Karolinska University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Security and effect data from another ongoing study.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-23
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Clinical trial NCT04376684: Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
Official title: A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
Acronym: OSCAR
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 1156.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-05-28
Primary completion date: 2021-07-15
Completion date: 2021-08-16
Baseline population: Baseline characteristics were presented for Enrolled Population.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT04724772: Use of Tranexamic Acid in Blepharoplasties
Official title: Comparison of Clinical Outcomes Following Upper Lid Blepharoplasty With and Without Tranexamic Acid as an Additive to Traditional Local Anesthetic.
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Stopped study due to pharmacy issues before treating patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-20
Primary completion date: 2023-07-20
Completion date: 2023-09-20
Plan to share individual participant data: NO
Clinical trial NCT05317312: Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
Official title: A Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Response Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
Sponsor: Viatris Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 111.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-03-31
Primary completion date: 2022-06-15
Completion date: 2022-06-20
Clinical trial NCT03373877: Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
Official title: A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Sponsor: Samus Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Samus is focusing all of their efforts in myelofibrosis on the new oral formulation of PU-H71.
Enrollment: 4.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-05-24
Primary completion date: 2019-10-17
Completion date: 2020-03-10
Plan to share individual participant data: NO
Clinical trial NCT02111798: Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence
Official title: Bupropion-Enhanced CM for Cocaine Dependence
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 83.0 (ACTUAL)
Number of arms: 4.0
Start date: 2014-07-31
Primary completion date: 2020-05-31
Completion date: 2021-01-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05961696: A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Official title: A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: 0 accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-07-05
Primary completion date: 2023-10-03
Completion date: 2023-10-03
Clinical trial NCT03696212: Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Official title: Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
Sponsor: Arrys Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Based on the totality of the generated combined safety and efficacy data in the interim period, the company decided to terminate the combination study in NSCLC patients. There are no subjects on study drug at this time or in the EOT Follow-up period.
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-08
Primary completion date: 2021-02-15
Completion date: 2021-02-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03395288: Nutraceutical Efficacy for rUTI
Official title: Randomized, Controlled Trial to Determine the Efficacy of Nutraceutical vs Control as Non-antibiotic Prophylaxis for Recurrent Urinary Tract Infection in Postmenopausal Women Using Vaginal Estrogen Therapy
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Performed a futility analysis and determined that study objectives could not be met.
Enrollment: 61.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-03-22
Primary completion date: 2020-04-25
Completion date: 2020-04-25
Limitations and caveats: The primary limitation of this study was the low recruitment and retention encountered. Study retention was lower than expected. A futility analysis was performed at the interim analysis and we found that we do not have power to detect the effect size difference that we originally estimated.
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share individual participant data
Clinical trial NCT04042506: SBRT as a Vaccination for Metastatic Melanoma
Official title: In Situ Vaccination With Stereotactic Body Radiation Therapy (SBRT) as a Strategy to Overcome Resistance to Immune Checkpoint Blockade: a Phase II Clinical Trial of SBRT and Anti-PD-1 Therapy With Immunologic Correlates
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to enroll patients in this study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-26
Primary completion date: 2019-11-26
Completion date: 2021-01-26
Plan to share individual participant data: NO
Clinical trial NCT03477006: Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial
Official title: Pragmatic Prehospital Group O Whole Blood Early Resuscitation (PPOWER) Trial: A Prospective, Interventional,Randomized, 3 Year, Pilot Clinical Trial
Acronym: PPOWER
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Slow enrollment, financial considerations and global pandemic
Enrollment: 86.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-20
Primary completion date: 2020-10-30
Completion date: 2020-10-30
Plan to share individual participant data: NO
Clinical trial NCT04752566: A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
Official title: A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-08
Primary completion date: 2022-08-03
Completion date: 2022-08-03
Baseline population: Full analysis set included all randomized participants who received at least 1 dose of study drug and had a baseline functional grade (FG) score and at least 1 postbaseline FG score.
Plan to share individual participant data: NO
Clinical trial NCT04158141: Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
Official title: Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
Sponsor: NRG Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Permanent Administrative Closure
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-29
Primary completion date: 2023-11-20
Completion date: 2023-11-20
Clinical trial NCT03170518: A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
Official title: A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 171.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-21
Primary completion date: 2023-09-20
Completion date: 2023-09-20
Clinical trial NCT02595918: Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
Official title: A Pilot Study of Preoperative Nivolumab in High-Risk Non-Metastatic and Metastatic Renal Cell Carcinoma
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inadequate accrual rate
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-05-19
Primary completion date: 2020-08-01
Completion date: 2020-08-01
Clinical trial NCT03354598: Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
Official title: A Prospective Phase 3 Randomized Multi-center Double-blind Study of Efficacy Tolerability & Safety of Oral Sulopenem-etzadroxil/Probenecid vs Ciprofloxacin for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women
Sponsor: Iterum Therapeutics, International Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1671.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-01
Primary completion date: 2020-01-16
Completion date: 2020-01-20
Baseline population: Intent to Treat (ITT) Participants
Plan to share individual participant data: NO
Clinical trial NCT03312244: Pyridostigmine as Immunomodulator in People Living With HIV
Official title: Study of the Role of Peripheral Acetylcholinesterase Inhibitor Pyridostigmine as Immunomodulators in a Population of Patients Living With Human Immunodeficiency Virus Infection.
Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Due to COVID-19, effective 3/19/2020 recruitment is halted until further notice
Enrollment: 60.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-07-01
Primary completion date: 2021-06-30
Completion date: 2022-06-30
Plan to share individual participant data: YES
IPD sharing description: All data will be freely available to all research parties involved
IPD time frame: Data will be available after finishing with recruitment.
IPD access criteria: Data will be made available by request.
Clinical trial NCT04140695: Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
Official title: A Randomized, Double-blind, Placebo-controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis
Sponsor: Vanda Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 87.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-21
Primary completion date: 2020-10-14
Completion date: 2020-10-14
Limitations and caveats: This study was discontinued early and therefore the study was not powered for appropriate examination of primary and secondary endpoints.
Clinical trial NCT03433833: Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing
Official title: Phase 1 Study of Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing
Sponsor: University of Illinois at Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study Not Funded
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-10
Primary completion date: 2024-04-16
Completion date: 2024-12-31
Plan to share individual participant data: NO
IPD sharing description: The research data will be shared with the co-investigators and the referring physicians.
Clinical trial NCT05641298: Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
Official title: A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Acronym: REPRIEVE
Sponsor: Aceragen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Corporate finances
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-10
Primary completion date: 2023-09-30
Completion date: 2023-09-30
Clinical trial NCT04594681: A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
Official title: A Phase I Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
Sponsor: Kyowa Kirin Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The Sponsor judged that the objectives of this Phase 1 study were satisfied, and the study was terminated after the completion of Cohort 3 Step 3.
Enrollment: 116.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-16
Primary completion date: 2022-08-26
Completion date: 2022-08-26
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03317002: AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
Official title: A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)
Acronym: FLAVOUR
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 129.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-10-30
Primary completion date: 2020-04-08
Completion date: 2020-04-08
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04526288: CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Official title: A Randomized Trial for Patients With High-Grade Myeloid Neoplasms With Measurable Residual Disease (MRD): CPX-351 vs. Immediate Allogeneic Hematopoietic Cell Transplantation
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to low accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-09
Primary completion date: 2023-08-27
Completion date: 2023-08-27
Baseline population: Single Arm A participant followed for survival only.
Limitations and caveats: Low accrual lead to early termination of the study. The single individual enrolled was randomized to the non-investigational arm of the study (Arm A) and was removed from the study prior to conditioning which only allowed for follow-up of overall survival. Therefore, there is little to no interpretable data to report.
Plan to share individual participant data: NO
Clinical trial NCT04524962: Study of Descartes-30 in Acute Respiratory Distress Syndrome
Official title: Phase I/IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome
Sponsor: Cartesian Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Phase 1 enrollment completed. Further clinical development terminated
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-23
Primary completion date: 2022-09-09
Completion date: 2023-09-09
Clinical trial NCT04315298: Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Official title: An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 1912.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-03-18
Primary completion date: 2020-07-24
Completion date: 2020-09-02
Plan to share individual participant data: YES
IPD sharing description: All IPD that underlie publicly available results will be considered for sharing
IPD time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification
IPD access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Clinical trial NCT04676061: Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™
Official title: Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™; a Randomized Double-Blinded Placebo-Controlled Trial
Sponsor: Baylor Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: It was in the best interest of the investigator to terminate the study earlier than anticipated.
Enrollment: 51.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-11
Primary completion date: 2022-07-18
Completion date: 2023-03-10
Plan to share individual participant data: NO
Clinical trial NCT03952832: Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
Official title: Phase 2 Trial of Leflunomide in Patients With High-Risk Smoldering Multiple Myeloma
Sponsor: City of Hope Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Budget issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-11
Primary completion date: 2021-06-11
Completion date: 2021-06-11
Clinical trial NCT03238300: Neuroscience-Informed Treatment Development for Adolescent Alcohol Use
Official title: Neuroscience-Informed Treatment Development for Adolescent Alcohol Use
Sponsor: Medical University of South Carolina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-16
Primary completion date: 2022-03-01
Completion date: 2022-03-01
Clinical trial NCT03802864: Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine
Official title: Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-04
Primary completion date: 2020-01-30
Completion date: 2020-01-30
Plan to share individual participant data: NO